Medicare Enrolled
Dr. Irina Zolotarevskaya, M.D.
Pulmonary Disease · Rego Park, NY
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Zolotarevskaya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Zolotarevskaya?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Zolotarevskaya
Dr. Irina Zolotarevskaya is a pulmonary disease specialist in Rego Park, NY, with 20 years of NPI registration. Based on federal Medicare data, Dr. Zolotarevskaya performed 7,991 Medicare services across 3,304 unique beneficiaries.
Between the years covered by Open Payments, Dr. Zolotarevskaya received a total of $7,131 from 29 pharmaceutical and/or device companies across 518 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Zolotarevskaya is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in NY
$7,131 industry payments
Medicare Practice Summary
Medicare Utilization ↗7,991
Medicare services
Top 3% in NY for pulmonary disease
3,304
Unique beneficiaries
$90
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~400 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, benralizumab, 1 mg | 2,652 | $130 | $394 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,353 | $114 | $550 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
1,175 | $37 | $348 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
638 | $55 | $373 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
623 | $53 | $341 |
| Nitric oxide gas level test A test that measures the level of nitric oxide gas in the body. |
557 | $18 | $109 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
170 | $8 | $20 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
136 | $17 | $85 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
127 | $13 | $275 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
110 | $32 | $197 |
| New patient office visit, complex (60-74 min) | 75 | $195 | $1,065 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
56 | $613 | $5,054 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
55 | $74 | $167 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
54 | $36 | $108 |
| Smoking cessation counseling, 4-10 minutes A brief counseling session focused on helping patients quit smoking and tobacco use. The provider spends 4 to 10 minutes discussing strategies and support for cessation. |
41 | $17 | $85 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
39 | $25 | $205 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
37 | $592 | $4,611 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
31 | $36 | $108 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
19 | $281 | $618 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
16 | $89 | $580 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
15 | $168 | $745 |
| Pneumococcal vaccine, 23-valent A vaccine that protects against 23 types of pneumococcal bacteria. It is used to prevent infections caused by these bacteria. |
12 | $131 | $321 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$7,131
Total received (2018-2024)
Avg $1,019/year across 7 years
Top 24% in NY for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
29
Companies
518
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,131 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$491
2023
$366
2022
$1,269
2021
$1,429
2020
$691
2019
$1,482
2018
$1,403
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Philips North America LLC
$406
PFIZER INC.
$63
GENZYME CORPORATION
$22
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Philips Electronics North America Corporation
$1,831
GlaxoSmithKline, LLC.
$1,153
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,096
AstraZeneca Pharmaceuticals LP
$425
Philips North America LLC
$406
Mylan Specialty L.P.
$333
AbbVie Inc.
$292
Advanced Respiratory, Inc
$197
Kowa Pharmaceuticals America, Inc.
$165
Baxter Healthcare
$154
Insmed, Inc.
$131
PFIZER INC.
$112
ADVANCED RESPIRATORY, INC
$109
Regeneron Healthcare Solutions, Inc.
$99
GENZYME CORPORATION
$94
Ironwood Pharmaceuticals, Inc
$87
Circassia Pharmaceuticals Inc
$78
Amgen Inc.
$67
Nestle HealthCare Nutrition Inc.
$43
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$42
Merck Sharp & Dohme LLC
$36
Mallinckrodt Hospital Products Inc.
$30
Merck Sharp & Dohme Corporation
$27
Mallinckrodt Enterprises LLC
$27
Genentech USA, Inc.
$27
ABBVIE INC.
$21
Teva Pharmaceuticals USA, Inc.
$16
Horizon Therapeutics plc
$16
Dynavax Technologies Corporation
$16
Top 3 companies account for 57.2% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · ACTHAR · AJOVY · ANORO · ANORO ELLIPTA · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · DUAKLIR PRESSAIR · DUEXIS · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · DreamStat Cpap Auto · DreamWear · Dymista · EVENITY · Esbriet · FASENRA · Heplisav-B · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · JANUVIA · JARDIANCE · LINZESS · Life 2000 Ventilation System · Linzess · Livalo · NUCALA · OFEV · PNEUMOVAX 23 · PREVNAR 13 · PREVNAR 20 · Perforomist · Prolia · QULIPTA · Respiratoriy Care Undiv · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · Sleep Other · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · The Monarch Airway Clearance System · The Vest System Model 105 Home Care · The VisiVest Airway Clearance System · Trilogy 100 · UBRELVY · VRAYLAR · Wellcentive Undiv · XIFAXAN · Yupelri · ZENPEP · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
637
Per 100K population
27.3
County median income
$84,961
Nearest hospital
ELMHURST HOSPITAL CENTER
1.2 mi
1.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Zolotarevskaya is a clinical cardiology specialist, with above-average Medicare volume (top 3% in NY), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Zolotarevskaya experienced with injection, benralizumab, 1 mg?
Based on Medicare claims data, Dr. Zolotarevskaya performed 2,652 injection, benralizumab, 1 mg services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Zolotarevskaya receive payments from pharmaceutical companies?
Yes. Dr. Zolotarevskaya received a total of $7,131 from 29 companies across 518 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Zolotarevskaya's costs compare to other pulmonary diseases in Rego Park?
Dr. Zolotarevskaya's average Medicare payment per service is $90. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Zolotarevskaya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Rego Park
Browse pulmonary diseases in Rego Park ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NY
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NY
Which NY pulmonary diseases receive the most from drug and device companies.
By company
Philips Electronics North America Corporation Payments to Doctors
See all physicians who received payments from Philips Electronics North America Corporation.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology